4CASTING the Future: Innovations in Triple Negative Breast Cancer

Triple negative breast cancer remains one of the most challenging types to treat because it lacks the common treatment targets, grows and spreads aggressively, is highly diverse and currently has limited effective therapies - but new research is changing the story.  

Associate Professor Rachel Dear takes us inside the 4CAST trial, showing how science moves from bench to bedside and what this could mean for the future of triple-negative breast cancer treatment. 

In this episode, we sit down with Rachel to discuss:

• (01:32) What makes triple-negative breast cancer so difficult to treat?
• (02:26) What pre-clinical findings led to the development of the 4CAST clinical trial?
• (08:37) The future of treatment for triple-negative breast cancer.

Tune in for a deep dive into this important research.

⁠⁠⁠Donate to Support Life-Saving Research⁠⁠⁠

Like this episode? ⁠⁠⁠Find more Breast Cancer Trials Podcast Episodes here⁠⁠⁠

Follow Breast Cancer Trials on Social Media: 

• Instagram:⁠ ⁠⁠@breastcancertrials⁠⁠⁠ 
• Facebook:⁠ ⁠⁠Breast Cancer Trials⁠⁠⁠ 
• LinkedIn: ⁠⁠⁠Breast Cancer Trials⁠⁠⁠ 
• X: ⁠⁠⁠@BCTrialsANZ⁠⁠⁠

Guest: Medical Oncologist Rachel Dear, from Sydney.

Thank you for listening! If you found this episode valuable, please share it with your loved ones and help spread awareness about triple-negative breast cancer.